Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder.
Trazodone (TZ) was administered to nine patients suffering from obsessive-compulsive disorder (OCD), who failed to respond to either clomipramine (CMI) or to CMI plus lithium carbonate. The group, as a whole, showed significant but mild improvement. Three patients responded very favorably to TZ. In these three responders, efficacy was substantiated by the return of the original obsessive-compulsive (OC) symptoms following TZ withdrawal and their amelioration after its readministration. Interestingly, the aggravation of OCD symptomatology that has been associated with a specific TZ metabolite was not observed. This study is consistent with previous reports of the anti-OC efficacy of TZ and suggests the involvement of complex serotonergic mechanisms in the pathophysiology of this disorder.
Hermesh
H
H
Gehah Psychiatric Hospital, Beilinson Medical Center, Petah Tikva, Israel.
Aizenberg
D
D
Munitz
H
H
D000328:Adult; D000704:Analysis of Variance; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008094:Lithium / Q000097:blood / Q000627:therapeutic use; D016651:Lithium Carbonate; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D011446:Prospective Studies; D014196:Trazodone / Q000627:therapeutic use*
D016651:Lithium Carbonate; D008094:Lithium; D002997:Clomipramine; D014196:Trazodone